Review article · 2021 · Open access

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Yuao Wu, Karla X. Vazquez‐Prada, Yajun Liu, Andrew K. Whittaker, Run Zhang, Hang Thu Ta

Nanotheranostics, 5(4), 499–514 · Published 1 January 2021 · DOI 10.7150/ntno.62730

Open PDFView at the publisherCite this paper

In brief

“Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases” is a 2021 review article by Yuao Wu and 5 co-authors, published in Nanotheranostics. OpenAlex counts 97 citations as of 21 November 2026, which puts it in the top 3% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Nanotheranostics.

Citations
97
Most cited in
2024 (25)
Field-weighted impact
1.17
References
141
Authors
6

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a group of disorders of the heart and blood vessels such as myocardial infarction, ischemic heart, ischemic injury, injured arteries, thrombosis and atherosclerosis. Amongst these, atherosclerosis is the dominant cause of CVD and is an inflammatory disease of the blood vessel wall. Diagnosis and treatment of CVD remain the main challenge due to the complexity of their pathophysiology. To overcome the limitations of current treatment and diagnostic techniques, theranostic nanomaterials have emerged. The term "theranostic nanomaterials" refers to a multifunctional agent with both therapeutic and diagnostic abilities. Theranostic nanoparticles can provide imaging contrast for a diversity of techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT). In addition, they can treat CVD using photothermal ablation and/or medication by the drugs in nanoparticles. This review discusses the latest advances in theranostic nanomaterials for the diagnosis and treatment of CVDs according to the order of disease development. MRI, CT, near-infrared spectroscopy (NIR), and fluorescence are the most widely used strategies on theranostics for CVDs detection. Different treatment methods for CVDs based on theranostic nanoparticles have also been discussed. Moreover, current problems of theranostic nanoparticles for CVDs detection and treatment and future research directions are proposed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wu, Y., Vazquez‐Prada, K. X., Liu, Y., Whittaker, A. K., Zhang, R., & Ta, H. T. (2021). Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics, 5(4), 499–514. https://doi.org/10.7150/ntno.62730

MLA 9

Wu, Yuao, et al. “Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases.” Nanotheranostics, vol. 5, no. 4, 2021, pp. 499–514. https://doi.org/10.7150/ntno.62730.

Chicago

Wu, Yuao, Karla X. Vazquez‐Prada, Yajun Liu, Andrew K. Whittaker, Run Zhang, and Hang Thu Ta. 2021. “Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases.” Nanotheranostics 5 (4): 499–514. https://doi.org/10.7150/ntno.62730.

Harvard

Wu, Y. et al. (2021) ‘Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases’, Nanotheranostics, 5(4), pp. 499–514. doi:10.7150/ntno.62730.

IEEE

Y. Wu, K. X. Vazquez‐Prada, Y. Liu, A. K. Whittaker, R. Zhang, and H. T. Ta, “Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases,” Nanotheranostics, vol. 5, no. 4, pp. 499–514, 2021, doi: 10.7150/ntno.62730.

BibTeX

@article{wu2021recent,
  title     = {{Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases}},
  author    = {Wu, Yuao and Vazquez‐Prada, Karla X. and Liu, Yajun and Whittaker, Andrew K. and Zhang, Run and Ta, Hang Thu},
  journal   = {Nanotheranostics},
  year      = {2021},
  volume    = {5},
  number    = {4},
  pages     = {499--514},
  doi       = {10.7150/ntno.62730},
  url       = {https://doi.org/10.7150/ntno.62730}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202155
202299
20232121
20242525
20252323
20261414

Its field-weighted citation impact is 1.17: it has been cited 1.17 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics

  • theranostic nanoparticles
  • cardiovascular disease
  • atherosclerosis
  • theranostic nanomaterials
  • magnetic resonance imaging contrast
  • positron emission tomography
  • computed tomography contrast
  • near-infrared spectroscopy

Work with this paper

Most-cited papers in Engineering

All highly cited Engineering papers

Questions about this paper

How do I cite this paper in APA style?

Wu, Y., Vazquez‐Prada, K. X., Liu, Y., Whittaker, A. K., Zhang, R., & Ta, H. T. (2021). Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics, 5(4), 499–514. https://doi.org/10.7150/ntno.62730

How many times has this paper been cited?

97 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nanotheranostics: sign in and open the PDF from this page.

Who wrote this paper?

Yuao Wu, Karla X. Vazquez‐Prada, Yajun Liu, Andrew K. Whittaker, Run Zhang, Hang Thu Ta.

What is the DOI of this paper?

10.7150/ntno.62730, permanently at https://doi.org/10.7150/ntno.62730. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.